T47D/S5 Cell Line

Catalogue number: 152111
Sub-type: Continuous
Images:

Contributor

Inventor: Anne Lykkesfeldt
Institute: Danish Cancer Society, Denmark
Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: T47D/S5 Cell Line

Alternate name:

Class:
Conjugate:
Description: The T47D/S5 cell line is a control cell line for the fulvestrant (Faslodex) resistant T47D/182R-1 and T47D/182R-2 cell lines. T47D/S5 is adherent and the morphology is polygonal epithelial. The cell passage number is 155 (AL3043, AL3044). T47D/S5 cells express oestrogen receptor alpha and progesterone receptor. This cell line allows the study of the mechanisms involved in fulvestrant resistant breast cancer cell growth.
Purpose:
Parental cell: T47D
Organism: Human
Tissue: Breast
Model: Tumour line
Gender:
Isotype:
Reactivity:
Selectivity:
Host:
Immunogen:
Immunogen UNIPROT ID:
Sequence:
Growth properties:
Production details: T47D/S5 cells grows continuously in presence of 5% fetal calf serum.
Formulation:
Recommended controls:

Bacterial resistance:
Selectable markers:
Additional notes:

Target details

Target: Oestrogen receptor

Target alternate names:

Target background:

Molecular weight:

Ic50:

Applications

Application: Determining molecular mechanisms around fulvestrant resistance
Application notes:

Handling

Format: Frozen
Concentration:
Passage number: Passage 155 (AL3043, AL3044)
Growth medium: Phenol red free RPMI 1640 + 5% FCS + glutamax + 8ug Insulin/ml
Temperature: 37° C
Atmosphere: 5% CO2
Volume:
Storage medium:
Storage buffer:
Storage conditions:
Shipping conditions: Dry ice

Related tools

Related tools:

References

References: Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943. ; Larsen et al. 2015.

BMC Cancer. 15:239. PMID: 25885472. ; Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. ; SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment. ; Thrane et al. 2014. Oncogene. :. PMID: 25362855. ; A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.